KSQ Therapeutics is at the forefront of developing innovative cancer therapies through its proprietary CRISPRomics® platform, which enables the identification of critical therapeutic targets within the genome. This platform allows for genome-scale knockouts across various immune and cancer cell types, facilitating the discovery of high-value targets such as SOCS1, Regnase-1, and USP1. The company is advancing its engineered Tumor Infiltrating Lymphocytes (eTIL®) programs, particularly KSQ-001EX and KSQ-004EX, which utilize CRISPR/Cas9 gene editing to enhance anti-tumor activity. These therapies aim to overcome biological challenges in treating solid tumors, with ongoing clinical trials assessing their safety and efficacy in patients with treatment-refractory cancers.

In addition to its eTIL programs, KSQ Therapeutics is developing KSQ-4279, a first-in-class small-molecule inhibitor of USP1, which plays a crucial role in DNA damage response. This compound is being evaluated in clinical trials for its potential to enhance treatment outcomes, particularly in combination with PARP inhibitors. The company employs its ExPRESS™ manufacturing process to streamline the production of its eTIL therapies, significantly reducing the time and complexity traditionally associated with TIL manufacturing. By leveraging these advanced technologies, KSQ Therapeutics aims to deliver transformational medicines with curative potential to a broad patient population.

United States

KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed. The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates.

KSQ Therapeutics

Company Details